RESUMO
This study evaluated whether the treatment of pseudopregnancy in bitches with vitamin B6 modulates uterine expression of receptors for progesterone (PR), oestrogen (ERα), androgen (AR), thyroid hormone (TRα) and the kisspeptin/Kiss1r system. Eighteen pseudopregnant bitches were treated for 20 days in groups receiving placebo (n = 6); cabergoline (5 µg/kg/day; n = 6); or vitamin B6 (50 mg/kg/day; n = 6). Blood was collected on the 1st day of drug administration and 120 h later to measure serum prolactin (PRL). After treatment, they were ovariohysterectomized and uterine fragments were collected for histomorphometry and immunohistochemical evaluation of PR, ERα, AR, TRα, Kiss1 and Kiss1r. After 120 h of cabergoline or vitamin B6 treatment, PRL levels were reduced in the bitches, confirming the antiprolactinemic effect of these drugs. Furthermore, regardless of treatment, the animals exhibited uterine histomorphometry consistent with dioestrus. The PR showed strong immunostaining in all regions and an increase in scores was observed for this receptor in animals treated with vitamin B6 in deep glands. In contrast, ERα and Kiss1R receptors showed weak to no immunostaining in all uterine regions and no changes between groups. Regarding AR, most animals treated with vitamin B6 showed increased trends in the deep gland and myometrium marking scores. In contrast, in both vitamin B6 and cabergoline treatments, a reduction in TRα marking scores was observed compared to the control group. In addition, on the endometrial surface, a reduction was observed in the marked area of Kiss1 after administration of cabergoline when compared to the pseudopregnant control group. These findings shed valuable insight into the use of vitamin B6 as a drug with actions similar to cabergoline in reducing PRL and uterine modulation in bitches.
Assuntos
Cabergolina , Kisspeptinas , Prolactina , Pseudogravidez , Útero , Animais , Feminino , Cães , Kisspeptinas/farmacologia , Kisspeptinas/metabolismo , Útero/efeitos dos fármacos , Útero/metabolismo , Cabergolina/farmacologia , Prolactina/metabolismo , Pseudogravidez/veterinária , Pseudogravidez/metabolismo , Receptores de Progesterona/metabolismo , Receptores Androgênicos/metabolismo , Ergolinas/farmacologiaRESUMO
Dendritic cells (DCs) are known as antigen-presenting cells that are capable of regulating immune responses. DCs and T cells can interact mutually to induce antigen-specific T-cell responses. Cabergoline, which is a dopamine (DA) receptor agonist, seems to implement anti-inflammatory properties in the immune system, and therefore in the present study the impact of a DA receptor agonist cabergoline on the monocyte-derived DCs (moDCs) was assessed. Immature moDCs were treated with lipopolysaccharide to produce mature DCs (mDCs). The expression of DCs' related surface markers namely: CD11c, HLA-DR, and CD86 was measured by utilizing of flow cytometry. Real-time PCR was the technique of choice to determine the levels at which diverse inflammatory and anti-inflammatory factors in cabergoline-treated and control mDC groups were expressed. DCs treated with cabergoline displayed a significant decrease in CD86 and HLA-DR expression, markers linked to maturation and antigen presentation, respectively. In addition, the cabergoline-mDC group showed a considerable decline in terms of the levels at which IL-10, TGF-ß, and IDO genes were expressed, and an increase in the expression of TNF-α and IL-12 in comparison to the mDC control group. Our findings revealed that cabergoline as an immunomodulatory agent can relatively shift DCs into an immunogenic state, and there is a requirement for further investigations to evaluate the effects of cabergoline-treated DCs on the T cell responses in vitro, and also in various diseases including cancer in animal models.
Assuntos
Cabergolina , Células Dendríticas , Agonistas de Dopamina , Monócitos , Humanos , Células Dendríticas/efeitos dos fármacos , Células Dendríticas/metabolismo , Células Dendríticas/imunologia , Cabergolina/farmacologia , Agonistas de Dopamina/farmacologia , Monócitos/efeitos dos fármacos , Monócitos/metabolismo , Monócitos/imunologia , Monócitos/citologia , Fenótipo , Ergolinas/farmacologia , Células Cultivadas , Lipopolissacarídeos/farmacologiaRESUMO
Adolescence is a phase of substantial changes in the brain, characterized by maturational remodeling of many systems. This remodeling allows functional plasticity to adapt to a changing environment. The dopaminergic system is under morphological and physiological changes during this phase. In the present study, we investigated if changes in the dopaminergic tone alter mice behavior in a receptor and sex-specific manner, specifically at the beginning of the puberty period. We administered L-Dopa, SKF-38393 (D1 dopamine receptor agonist), and Quinpirole (D2 dopamine receptor agonist) and tested male and female mice's motor, anxiety- and depressive-like behavior. While females displayed an impaired exploratory drive, males presented an intense depressive-like response. Our results provide insights into the function of dopaminergic development in adolescent behavior and highlight the importance of studies in this time window with male and female subjects.
Assuntos
Agonistas de Dopamina , Levodopa , Humanos , Camundongos , Masculino , Feminino , Animais , Adolescente , Quimpirol/farmacologia , Levodopa/farmacologia , 2,3,4,5-Tetra-Hidro-7,8-Di-Hidroxi-1-Fenil-1H-3-Benzazepina/farmacologia , Agonistas de Dopamina/farmacologia , Dopaminérgicos/farmacologia , Ergolinas/farmacologia , Receptores de Dopamina D1 , Dopamina , Ansiedade/tratamento farmacológicoRESUMO
Hemos evaluado en un estudio clínico con grupo control, los efectos de la Nicergolina en 2 grupos de niños, uno con retardo psicomotriz por Hipoxia neonatal y otro con disfunción cerebral mínima. Se evaluaron las variaciones en el EEG, y se efectuaron evaluaciones psicológicas, antes y después del tratamiento. Encontramos que todos los niños que recibieron el tratamiento presentaron una mejoría significativa, aunque durante el estudio, no se realizó estimulación temprana ni fisioterapia. Las pruebas estadísticas revelan una significación importante en los resultados; después de 30-45 días de tratamiento a una dosis de 15-30 mg/24 horas